Mass., Nov 10, 2011 (BUSINESS WIRE) — Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the idiopathic pulmonary fibrosis (IPF) drug market is forecasted to grow to $4.6 billion in 2020 in the United States and Europe.
Increasing diagnosed and drug-treated populations and the launch of five drugs with novel mechanisms of action are key drivers of this growth. Idiopathic pulmonary fibrosis is one of the most common interstitial lung diseases, and it is the most prevalent pulmonary fibrotic disease.
Read the entire article at:
or go to www.ipftoday.com for more news.